20
2019-08
mTOR Inhibitor Developed by Suzhou Kintor Obtained Approval for Clinical Trials in China
[Suzhou, August 20, 2019] National Medical Products Administration officially granted a clinical trial approval to Suzhou Kintor Pharmaceuticals, Inc. ("Suzhou Kintor") on commencement of clinical trials of the drug (GT0486) as an mTOR inhibitor. The drug (GT0486) is a novel mTORC1 / mTORC2 inhibitor (the second generation of mTOR inhibitor) which is indicated for advanced solid tumors. Currently, there is no second generation of mTOR inhibitors on the market in China, and there are huge unmet clinical needs in the research area.
19
2019-08
[Suzhou, August 19, 2019]Suzhou Kintor Pharmaceuticals, Inc. (“Suzhou Kintor") and CMAB Biopharma (Suzhou) Inc. ("CMAB") announced together a comprehensive strategic cooperation agreement on the development and production of ALK-1 monoclonal antibody in Suzhou Biopharma Industrial Park (BioBAY).
21
2019-06
Suzhou Kintor Won "Extraordinary Biopharmaceutical Enterprise Award" of China Financing in 2019
[June 21, 2019, Hong Kong, China] The awarding ceremony of the "2019 China Financing Awards" sponsored by "China Financing", a high-end financial magazine on Hong Kong capital market, was successfully held in Hong Kong. Suzhou Kintor Pharmaceuticals, Inc. ("Suzhou Kintor"), together with nine pharmaceutical enterprises such as WuXi Biologics, Henlius, CanSinoBio, Innovent Biologics and Hua Medicine, won "Extraordinary Biopharmaceutical Enterprise Award" of China Financing in 2019. Dr. Youzhi Tong, Chairman and Chief Executive Officer of Suzhou Kintor , was invited to attend the ceremony and accept the award on behalf of the company.
29
2018-10
Blockbuster news! 2018 Dongsha Lake [Venture Capital] Annual List Came out!
The 2018 Dongsha Lake [Venture Capital] Carnival sponsored by Oriza Holdings was held in Suzhou Industrial Park on October 29. Top fund investors,fund managers,and outstanding entrepreneurs in domestic private equity investment industry gathered in Dongsha Lake Fund Town to discuss the future development of Chinese venture capital industry and share their insights on industry trends and investment logic.
31
2018-07
Dr. Youzhi Tong of Suzhou Kintor: Entering the Spring for Innovative Drug Development
Dr. Youzhi Tong hopes that Suzhou Kintor is not merely a company that only addresses local pharmaceutical needs,but rather a company with a global product layout.
25
2018-06
Suzhou Kintor’s Dr. Youzhi Tong: In the Name of Father
Aspiring to become an academic expert,Dr. Tong accidentally entered the entrepreneurial circle. Under his leadership,Kintor Pharmaceuticals combines independent research and development with external introductions,develops innovative drug Proxalutamide,and works with Pfizer to develop ALK-1 in an attempt to build a leading anti-tumor innovative drug company in China.